Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia

NCT00665990 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Refractory Solid Tumors
Leukemia

Interventions

DRUG: Bevacizumab
DRUG: Sorafenib
DRUG: Cyclophosphamide

Sponsor

St. Jude Children's Research Hospital